| abstract |
1. The compound of formula (I)! ! wherein ! R1 is hydrogen or alkyl; ! R2 is an unsubstituted or substituted heterocycle or! R2 is unsubstituted or substituted aryl; ! R3 is alkyl or halogen; ! X denotes an ordinary bond or alkanediyl group, which optionally includes one or more oxygen atoms, or carbonyl groups, or carbonyloxy groups in the form of a free base or an acid addition salt. ! 2. The compound of formula (I) according to claim 1, in which X denotes an ordinary bond. ! 3. The compound of formula (I) according to claim 1 or 2, in which R3 is chlorine. ! 4. The transisomer of the compounds of formula (I) according to any one of the preceding paragraphs. ! 5. A method for producing a compound of formula (I) according to claim 1 or a salt thereof, which comprises the reaction steps of a compound of formula (II)! ! in which R1 and R3 are as defined in claim 1, with a compound of formula (III)! ! in which X and R2 are as defined in claim 1, and isolating the resulting compound of formula (I) in the form of a free base or an acid addition salt. ! 6. The compound according to claim 1 in the form of a free base or a pharmaceutically acceptable acid addition salt for use as a pharmaceutical. ! 7. The compound according to claim 1 in the form of a free base or a pharmaceutically acceptable acid addition salt for use in preventing, treating or delaying the progression of disorders associated with irregularity of glutamatergic signal transmission, disorders of the gastrointestinal tract and urinary tract and nervous system, fully or partially mediated by mGluR5. ! 8. The pharmaceutical composition |